Rapamycin has had a bruising couple of weeks in the longevity press. The RAPA-EX-01 trial was the first randomized, double-blind, placebo-controlled study to pair weekly sirolimus with an exercise program in older adults.1 Its conclusion: The drug didn’t enhance functional gains from training, and appears to have modestly blunted them. Predictably, the headlines framed it as a stumble for the darling longevity drug at its first real test in humans. Some commentators have gone further, suggesting we should fold up the tent on rapamycin altogether.
I want to push back on that interpretation. But before getting into the details of the trial, it’s worth being explicit about how I think about evidence in this space. My prior on rapamycin in humans is already fairly conservative, largely because we lack meaningful long-term outcome data, even in the face of strong animal data and a plausible mechanism. So the key question is not whether a single short-term human study produces a negative result, but how much that result should update our confidence. In my view, RAPA-EX-01 represents a small additional update in the negative direction on one narrow dimension, namely muscle adaptation under these specific conditions, but it does not materially resolve the broader uncertainty around rapamycin’s effects on the major drivers of aging and mortality.
RAPA-EX-01 was designed to test a specific mechanistic hypothesis under specific conditions, and those conditions look almost nothing like the setup that would be needed to evaluate whether rapamycin is a broadly useful tool against aging, and the diseases of aging that actually kill people. So, before anyone declares the case closed, it’s worth being precise about what this trial did, and more importantly, what it couldn’t do.
The trial
Rapamycin inhibits mTORC1 (mechanistic target of rapamycin complex 1), a central signaling hub for protein synthesis, and thus muscular hypertrophy—and decades of rodent work and preliminary human studies have shown that high-dose, continuous rapamycin blocks the muscle-building response to overload. Why, then, would anyone give the drug to older adults who are trying to gain muscle from exercise?
Part of the answer lies in what’s come to be called the “cycling hypothesis.” More recent preclinical data suggest that low-dose or intermittent rapamycin can spare—and in some cases enhance—functional adaptations in aged animals, while still providing the autophagy-promoting, geroprotective effects that make the drug interesting in the first place. The idea is that you might be able to separate the anabolic window (during and after exercise) from the catabolic-autophagic window (driven by drug exposure), deliberately alternating mTORC1 activation and inhibition across the week.
Another part of the answer lies in the paradoxical disconnect between mTORC1 signaling and anabolic resistance. Anabolic resistance is the finding in most studies that exercise and amino acids trigger less muscle protein synthesis in older people’s muscles than they do in younger people’s. You might think that this would result from an age-related suppression of mTORC1 signaling, but surprisingly, signaling through mTORC1 is paradoxically elevated in aging mouse and human muscle.2,3,4 And in a 20-week resistance training study in humans, a gene expression analysis found that those who had evidence of lower basal mTOR signaling gained the most lean mass.5
This suggests that some rapamycin regimen that inhibits the age-related hyperactivity of mTOR might counterintuitively resolve age-related anabolic resistance and improve older people’s response to resistance training. In support of this idea, a low dose of rapamycin blunted the age-related loss of muscle mass and fiber-type cross-sectional area in some muscle groups in aged sedentary mice.6
RAPA-EX-01 was the first human trial designed to directly test that hypothesis.
The investigators randomized 40 sedentary adults aged 65–85 years to either 6 mg of rapamycin or matched placebo, once weekly for 13 weeks. Both groups performed an identical home-based exercise program three times per week: repeated 30-second chair-stands for resistance training and a stationary bike for endurance work. The primary outcome was the change in 30-second chair-stand repetitions from baseline to week 13. Dosing was timed for “Day 6” of each training week, roughly 24 hours after the last exercise session, to avoid interfering with the peak of post-exercise anabolic signaling.
The investigators analyzed the data two ways: an intention-to-treat (ITT) analysis and two prespecified sensitivity analyses. In an ITT analysis, the data from all subjects who are randomized to either the drug or the placebo are analyzed. This gives the most “real-world” analysis of a drug’s effects, because it includes things like people who drop out because the drug’s side effects are intolerable. On the other hand, it’s also informative to know what happened to the people who actually followed the protocol through to the end.
Both groups in the trial improved their performance in response to exercise. However, in the ITT analysis, participants in the rapamycin arm improved less than the subjects in the placebo group, by an average of approximately 2 fewer sit-to-stand movements by week 13 (adjusted mean difference between groups: −2.13; 95% CI:−4.61–0.34; p=0.089). This result was not statistically significant, but the direction of effect consistently favored placebo. The magnitude of the difference was also modest, on the order of a couple of repetitions over 30 seconds, which makes it difficult to know how clinically meaningful this effect would be even if it were real. However, the difference did reach significance in the prespecified sensitivity analyses—a complete-case analysis (p=0.045) and a per-protocol analysis (p=0.007), which included the most adherent of all the subjects in both groups. These analyses offer useful sensitivity checks, but because they exclude participants who dropped out or didn’t adhere to the protocol, they are also more vulnerable to bias than the ITT analysis.
Secondary functional outcomes all pointed in the same direction, though none reached significance: The 6-minute walk distance difference was −4.87 meters (p=0.706), and grip strength was −1.19 kg (p=0.344), each favoring the placebo arm over rapamycin; there was even a slight trend toward inferior outcomes in the rapamycin group on the Short Form 36 (SF-36), a questionnaire that measures quality of life across eight physical and mental health domains. While each of these comparisons is individually underpowered, the consistency in direction across multiple endpoints raises the possibility that the observed effect is not purely noise.
There were also a couple of safety signals that are worth watching for in future trials. There was a statistically significant but very small increase in HbA1c in the rapamycin group, and one case of pneumonia. Impaired glucose tolerance and immune inhibition are things we see in the rodent studies and in patients who use rapamycin for transplantation, so these are biologically plausible effects. On the other hand, we would not have expected to see them under this cyclic protocol, as they were not seen in Joan Mannick’s human studies, which used a similar protocol with a rapamycin analog.7
So what do we have? A small, exploratory trial in a specific population, using a specific dosing regimen, with a primary endpoint that missed significance under the prespecified primary analysis. That is a useful signal. It is not a verdict.
A reasonable counterargument, however, is that this study may be picking up a real and clinically relevant effect: that even intermittent mTOR inhibition in humans can impair functional adaptation to exercise, and that this signal, while modest here, could become more pronounced in larger or longer studies. If that interpretation is correct, it would meaningfully constrain how rapamycin could be used in practice, particularly in individuals for whom maintaining or improving muscle function is a primary goal.
Our research team spends hundreds of hours each month vetting studies and distilling dense literature to deliver evidence-informed insights on health and longevity. If you find value in our work, consider becoming a premium member and supporting our mission.
My thoughts
My reaction to this study is that it’s interesting but quite limited, and a long way from the death knell for rapamycin that some have framed it as. The trial is small—40 participants split across two arms—and the subjects don’t appear to have been training particularly hard. The resistance component was body-weight chair-stands with “density training” (more reps in the same window as fitness improved), and the endurance component was a progressive stationary bike protocol. That’s a reasonable design for a home-based, remotely supervised feasibility study in sedentary older adults, but it’s not a rigorous hypertrophy stimulus in the way a strength coach or muscle physiologist would construct one. That makes it difficult to know how applicable the findings are to people training at a higher level.
At the same time, it’s not obvious that a more demanding training program would eliminate the observed effect; if anything, one could argue that a stronger anabolic stimulus might amplify any interference with muscle adaptation. So while the training design limits generalizability, it doesn’t fully resolve how rapamycin would behave under more intensive conditions.
More importantly, even if we take the results at face value and assume they would hold up in a larger, better-controlled trial, the most this study suggests is that weekly rapamycin may have some negative impact on muscle adaptation under these specific conditions. What it does not address—at all—is rapamycin’s effect on the broader drivers of aging and mortality. People overwhelmingly die from cardiovascular disease, cancer, neurodegenerative disease, and metabolic disease. That constellation accounts for the vast majority of mortality risk in older adults.
Sarcopenia is clearly an important issue in aging, and I’ve written extensively about the importance of maintaining muscle mass and strength into old age, but it has to be considered in the context of those larger risks. The relevant question is not whether rapamycin has any negative effect on muscle adaptation, but whether any such effect is large enough to outweigh potential benefits on the major drivers of mortality. In other words, this is fundamentally a tradeoff problem: a modest impairment in muscle adaptation might be acceptable if it comes with a meaningful reduction in cardiovascular, oncologic, or neurodegenerative risk, but clearly unacceptable if it does not. So at worst, what we’re looking at here is a possible tradeoff—rapamycin may impair muscle growth under certain dosing and training conditions—but we have essentially no information about how that tradeoff balances against potential benefits across the much broader landscape of aging biology.
This also highlights a fundamental disconnect between animal data and short-term human trials. In animal models, rapamycin is studied over a large fraction of the lifespan, long enough to observe effects on survival and on the major age-related diseases that drive mortality. A 13-week human trial is structurally incapable of informing those outcomes. No set of biomarkers measured over that time horizon is going to meaningfully resolve whether rapamycin slows cardiovascular, metabolic, neurodegenerative, or oncologic disease—and those are the questions that actually determine whether the drug deserves a place in longevity medicine.
The bottom line
Stepping back, I don’t think RAPA-EX-01 meaningfully advances our understanding of the broader picture of rapamycin as a geroprotector beyond raising the possibility that it may impair muscle growth under certain dosing and training conditions. A larger study with a more demanding and clearly defined training stimulus—ideally with imaging or biopsy endpoints to directly assess muscle adaptation—would have been a much better way to isolate the question of how weekly rapamycin affects hypertrophy and exercise performance. And a longer follow-up would have been necessary to say anything meaningful about the outcomes that matter most for a putative geroprotector.
That said, Stanfield and colleagues deserve real credit for running a properly designed, double-blind, placebo-controlled RCT on a drug that has too often been discussed on the basis of animal data and n-of-1 enthusiasm. It’s also worth noting how this trial was funded: entirely through public donations, with the sample size explicitly capped by what a single site could run on that budget. If anything, this reinforces the case for the larger, longer, better-resourced trials the field actually needs.
Until we have data from those trials, I remain where I’ve been on rapamycin: curious, cautiously interested, and nowhere near ready to close the book. That said, this study does incrementally increase my concern that dosing, timing, and context will matter a great deal, and that any real-world use will require far more precision than the current discourse around rapamycin tends to acknowledge.
What would meaningfully change my mind would be either a larger, well-controlled human study showing a clear and clinically meaningful impairment in function or muscle mass across a range of training conditions, or, conversely, longer-term human data demonstrating benefits on hard clinical endpoints or well-validated surrogate markers of the diseases that actually drive mortality.
For a list of all previous weekly emails, click here.
References
1. Stanfield B, Leroux B, Kaeberlein M, Jones J, Lucas R. Exercise and weekly sirolimus (rapamycin) in older adults: RAPA-EX-01 randomised, double-blind, placebo-controlled trial. J Cachexia Sarcopenia Muscle. 2026;17(2):e70274.
2. Markofski MM, Dickinson JM, Drummond MJ, et al. Effect of age on basal muscle protein synthesis and mTORC1 signaling in a large cohort of young and older men and women. Exp Gerontol. 2015;65:1-7.
3. Tang H, Inoki K, Brooks SV, et al. mTORC1 underlies age-related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell. 2019;18(3):e12943.
4. Horwath O, Moberg M, Hodson N, et al. Anabolic sensitivity in healthy, lean, older men is associated with higher expression of amino acid sensors and mTORC1 activators compared to young. J Cachexia Sarcopenia Muscle. 2025;16(1):e13613.
5. Phillips BE, Williams JP, Gustafsson T, et al. Molecular networks of human muscle adaptation to exercise and age. PLoS Genet. 2013;9(3):e1003389.
6. Joseph GA, Wang SX, Jacobs CE, et al. Partial inhibition of mTORC1 in aged rats counteracts the decline in muscle mass and reverses molecular signaling associated with sarcopenia. Mol Cell Biol. 2019;39(19):1-16.7.
7. Mannick JB, Morris M, Hockey HUP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10(449):eaaq1564.
